Stable AP4 Variant Enhances T Cell Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current adoptive cellular immunotherapy methods face challenges in enhancing T cell expansion and effector differentiation, as existing T cell responses are short-lived and require continuous IL-2 signaling for AP4 protein expression, which is degraded quickly by the ubiquitin-proteasome pathway.
Innovation Solution
A mutated form of AP4 with increased stability, specifically the S139A mutation, is expressed in CD8+ T cells to prolong their activation and proliferation, allowing for sustained clonal expansion and effector differentiation even in the absence of IL-2, using a vector-based method for transfecting T cells with a polynucleotide sequence encoding this stable AP4 variant.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If wild-type AP4 is expressed in T cells, then T cell activation and proliferation are promoted, but the AP4 protein is rapidly degraded by the ubiquitin-proteasome pathway, limiting its duration of action
Solution Approach 1:
The patent applies parameter changes by modifying the amino acid sequence of AP4 at position 139 (serine to alanine substitution) to alter the protein's degradation rate. This single amino acid change reduces recognition by the ubiquitin-proteasome pathway, thereby extending the half-life and duration of AP4 protein expression in T cells without requiring continuous external stimulation.
2Productivity
If continuous IL-2 signaling is provided to maintain AP4 expression, then T cell expansion and effector differentiation are enhanced, but the complexity of the therapy increases and cost rises
Solution Approach 1:
The patent implements self-service by engineering T cells to autonomously produce stable AP4 protein that persists without requiring continuous external IL-2 signaling. The modified AP4 variant (S139A) maintains its function and stability independently, allowing the T cells to self-sustain their activated state and proliferative capacity through endogenous AP4 expression alone, thereby simplifying the therapeutic protocol.
3Duration of action of stationary object
If stable AP4 variant (S139A) is expressed in T cells, then prolonged T cell activation and clonal expansion are achieved, but the manufacturing process becomes more complex
Solution Approach 1:
The patent uses parameter changes by implementing a single amino acid substitution (S139A) in the AP4 sequence, which can be achieved through straightforward site-directed mutagenesis of the encoding nucleotide sequence. This minimal genetic modification allows the stable AP4 variant to be expressed using standard transfection methods without requiring complex manufacturing procedures, thus balancing extended duration of action with ease of production.
Data Source
AI summary
The present disclosure provides a mutated form of AP4 that is more resistant to degradation relative to wild-type AP4. The disclosure also provides T cells expressing the mutated form of AP4 and methods of using the T cells in adoptive cellular immunotherapy.